Identification
NameAldesleukin
Accession NumberDB00041  (BTD00082, BIOD00082)
TypeBiotech
GroupsApproved
Description

Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125.

Protein structureDb00041
Related Articles
Protein chemical formulaC690H1115N177O202S6
Protein average weight15314.8 Da
Sequences
>Aldesleukin sequence
MAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCL
EEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLN
RWITFCQSIISTLT
Download FASTA Format
Synonyms
125-L-serine-2-133-interleukin 2 (human reduced)
Interleukin-2 aldesleukin
Interleukin-2(2-133),125-ser
Recombinant interleukin-2 human
External IDs Not Available
Product Ingredients Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ProleukinInjection1.1 mg/mLIntravenousNovartis1992-05-062017-04-15Us
ProleukinInjection, powder, lyophilized, for solution1.1 mg/mLIntravenousPrometheus Laboratories1992-05-05Not applicableUs
ProleukinPowder, for solution22000000 unitIntravenousNovartis1995-12-31Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNIIM89N0Q7EQR
CAS number110942-02-4
Pharmacology
Indication

For treatment of adults with metastatic renal cell carcinoma.

Structured Indications
Pharmacodynamics

Used to treat renal cell carcinoma, Aldesleukin induces the enhancement of lymphocyte mitogenesis and stimulation of long-term growth of human interleukin-2 dependent cell lines, the enhancement of lymphocyte cytotoxicity, the induction of killer cell (lymphokine-activated (LAK) and natural (NK)) activity; and the induction of interferon-gamma production. IL-2 is normally produced by the body, secreted by T cells, and stimulates growth and differentiation of T cell response. It can be used in immunotherapy to treat cancer. It enhances the ability of the immune system to kill tumor cells and may interfere with blood flow to the tumor.

Mechanism of action

Aldesleukin binds to the IL-2 receptor which leads to heterodimerization of the cytoplasmic domains of the IL-2R beta and gamma(c) chains, activation of the tyrosine kinase Jak3, and phosphorylation of tyrosine residues on the IL-2R beta chain. These events led to the creation of an activated receptor complex, to which various cytoplasmic signaling molecules are recruited and become substrates for regulatory enzymes (especially tyrosine kinases) that are associated with the receptor. These events stimulate growth and differentiation of T cells.

TargetKindPharmacological actionActionsOrganismUniProt ID
Interleukin-2 receptor subunit betaProteinyes
agonist
modulator
HumanP14784 details
Interleukin-2 receptor subunit alphaProteinyes
agonist
modulator
HumanP01589 details
Cytokine receptor common subunit gammaProteinyes
agonist
HumanP31785 details
Related Articles
AbsorptionNot Available
Volume of distribution

0.18 l/kg

Protein bindingNot Available
MetabolismNot Available
Route of elimination

The pharmacokinetic profile of Proleukin is characterized by high plasma concentrations following a short IV infusion, rapid distribution into the extravascular space and elimination from the body by metabolism in the kidneys with little or no bioactive protein excreted in the urine. Following the initial rapid organ distribution, the primary route of clearance of circulating proleukin is the kidney. Greater than 80% of the amount of Proleukin distributed to plasma, cleared from the circulation and presented to the kidney is metabolized to amino acids in the cells lining the proximal convoluted tubules.

Half life

13 min-85 min

ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-Bromoepiandrosterone16-Bromoepiandrosterone may decrease the antineoplastic activities of Aldesleukin.Investigational
19-norandrostenedione19-norandrostenedione may decrease the antineoplastic activities of Aldesleukin.Experimental, Illicit
5-androstenedione5-androstenedione may decrease the antineoplastic activities of Aldesleukin.Experimental, Illicit
AcebutololThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Acebutolol.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Acetazolamide.Approved, Vet Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Aldesleukin.Approved
AlclometasoneAlclometasone may decrease the antineoplastic activities of Aldesleukin.Approved
AldosteroneAldosterone may decrease the antineoplastic activities of Aldesleukin.Experimental
AliskirenThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Aliskiren.Approved, Investigational
AmcinonideAmcinonide may decrease the antineoplastic activities of Aldesleukin.Approved
AmifostineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Amiloride.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Amiodarone.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Aldesleukin.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Amphotericin B.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Amyl Nitrite.Approved
Androstenedione4-Androstenedione may decrease the antineoplastic activities of Aldesleukin.Experimental, Illicit
AnecortaveAnecortave may decrease the antineoplastic activities of Aldesleukin.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Apraclonidine.Approved
AripiprazoleAripiprazole may increase the hypotensive activities of Aldesleukin.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Arsenic trioxide.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Atenolol.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Azilsartan medoxomil.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Aldesleukin.Experimental
BarbitalBarbital may increase the hypotensive activities of Aldesleukin.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Barnidipine.Approved
BCG vaccineThe therapeutic efficacy of Bcg can be decreased when used in combination with Aldesleukin.Investigational
Beclomethasone dipropionateBeclomethasone dipropionate may decrease the antineoplastic activities of Aldesleukin.Approved, Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Benazepril.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Bendroflumethiazide.Approved
BepridilThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Bepridil.Approved, Withdrawn
BetamethasoneBetamethasone may decrease the antineoplastic activities of Aldesleukin.Approved, Vet Approved
BetaxololThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Betaxolol.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Aldesleukin.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Bisoprolol.Approved
BortezomibThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Bortezomib.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Brimonidine.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Bromocriptine.Approved, Investigational
BudesonideBudesonide may decrease the antineoplastic activities of Aldesleukin.Approved
BumetanideThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Bupivacaine.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Aldesleukin.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Candesartan.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Captopril.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Carbetocin.Approved
CarteololThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Carteolol.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Carvedilol.Approved, Investigational
ChlorothiazideThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Chlorpromazine.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Chlorthalidone.Approved
CiclesonideCiclesonide may decrease the antineoplastic activities of Aldesleukin.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Cilnidipine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Clevidipine.Approved
ClobetasolClobetasol may decrease the antineoplastic activities of Aldesleukin.Investigational
Clobetasol propionateClobetasol propionate may decrease the antineoplastic activities of Aldesleukin.Approved
ClocortoloneClocortolone may decrease the antineoplastic activities of Aldesleukin.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Clofarabine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Clonidine.Approved
ClozapineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Clozapine.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Conivaptan.Approved, Investigational
Cortisone acetateCortisone acetate may decrease the antineoplastic activities of Aldesleukin.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Aldesleukin.Approved, Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Dapagliflozin.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Desflurane.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Aldesleukin.Approved
DesoximetasoneDesoximetasone may decrease the antineoplastic activities of Aldesleukin.Approved
Desoxycorticosterone PivalateDesoxycorticosterone Pivalate may decrease the antineoplastic activities of Aldesleukin.Experimental, Vet Approved
DexamethasoneDexamethasone may decrease the antineoplastic activities of Aldesleukin.Approved, Investigational, Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Dexmedetomidine.Approved, Vet Approved
DiatrizoateThe risk of a hypersensitivity reaction to Diatrizoate is increased when it is combined with Aldesleukin.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Diclofenamide.Approved
DiflorasoneDiflorasone may decrease the antineoplastic activities of Aldesleukin.Approved
DifluocortoloneDifluocortolone may decrease the antineoplastic activities of Aldesleukin.Approved
DifluprednateDifluprednate may decrease the antineoplastic activities of Aldesleukin.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Aldesleukin.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Aldesleukin.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Diltiazem.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Dipyridamole.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Aldesleukin.Approved, Investigational
DoxazosinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Doxazosin.Approved
DuloxetineAldesleukin may increase the orthostatic hypotensive activities of Duloxetine.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Enalaprilat.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Eplerenone.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Eprosartan.Approved
EquileninEquilenin may decrease the antineoplastic activities of Aldesleukin.Experimental
EquilinEquilin may decrease the antineoplastic activities of Aldesleukin.Approved
EsmololThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Esmolol.Approved
EstroneEstrone may decrease the antineoplastic activities of Aldesleukin.Approved
Estrone sulfateEstrone sulfate may decrease the antineoplastic activities of Aldesleukin.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Etacrynic acid.Approved
Ethiodized oilThe risk of a hypersensitivity reaction to Ethiodized oil is increased when it is combined with Aldesleukin.Approved
FelodipineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Felodipine.Approved, Investigational
FenoldopamThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Fenoldopam.Approved
FimasartanThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Fimasartan.Approved
FludrocortisoneFludrocortisone may decrease the antineoplastic activities of Aldesleukin.Approved
FlumethasoneFlumethasone may decrease the antineoplastic activities of Aldesleukin.Approved, Vet Approved
FlunisolideFlunisolide may decrease the antineoplastic activities of Aldesleukin.Approved, Investigational
Fluocinolone AcetonideFluocinolone Acetonide may decrease the antineoplastic activities of Aldesleukin.Approved, Investigational, Vet Approved
FluocinonideFluocinonide may decrease the antineoplastic activities of Aldesleukin.Approved, Investigational
FluocortoloneFluocortolone may decrease the antineoplastic activities of Aldesleukin.Approved, Withdrawn
FluorometholoneFluorometholone may decrease the antineoplastic activities of Aldesleukin.Approved
FluprednideneFluprednidene may decrease the antineoplastic activities of Aldesleukin.Approved, Withdrawn
FlurandrenolideFlurandrenolide may decrease the antineoplastic activities of Aldesleukin.Approved
Fluticasone furoateFluticasone furoate may decrease the antineoplastic activities of Aldesleukin.Approved
Fluticasone propionateFluticasone Propionate may decrease the antineoplastic activities of Aldesleukin.Approved
FormestaneFormestane may decrease the antineoplastic activities of Aldesleukin.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Fosinopril.Approved
FurosemideThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Furosemide.Approved, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Guanfacine.Approved, Investigational
HalothaneThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Halothane.Approved, Vet Approved
HE3286HE3286 may decrease the antineoplastic activities of Aldesleukin.Investigational
HexobarbitalHexobarbital may increase the hypotensive activities of Aldesleukin.Approved
HydralazineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneHydrocortisone may decrease the antineoplastic activities of Aldesleukin.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Hydroflumethiazide.Approved
IloprostThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Iloprost.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Imipramine.Approved
IndapamideThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Indapamide.Approved
IndoraminThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Indoramin.Withdrawn
Interferon Alfa-2a, RecombinantThe risk or severity of adverse effects can be increased when Interferon Alfa-2a, Recombinant is combined with Aldesleukin.Approved
Interferon Alfa-2b, RecombinantThe risk or severity of adverse effects can be increased when Interferon Alfa-2b, Recombinant is combined with Aldesleukin.Approved
Interferon alfa-n3The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Aldesleukin.Approved, Investigational
Interferon alfacon-1The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Aldesleukin.Approved
IodipamideThe risk of a hypersensitivity reaction to Iodipamide is increased when it is combined with Aldesleukin.Approved
IodixanolThe risk of a hypersensitivity reaction to Iodixanol is increased when it is combined with Aldesleukin.Approved
IohexolThe risk of a hypersensitivity reaction to Iohexol is increased when it is combined with Aldesleukin.Approved
IopamidolThe risk of a hypersensitivity reaction to Iopamidol is increased when it is combined with Aldesleukin.Approved
IopromideThe risk of a hypersensitivity reaction to Iopromide is increased when it is combined with Aldesleukin.Approved
IoversolThe risk of a hypersensitivity reaction to Ioversol is increased when it is combined with Aldesleukin.Approved
IoxilanThe risk of a hypersensitivity reaction to Ioxilan is increased when it is combined with Aldesleukin.Approved
IrbesartanThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Irbesartan.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Isradipine.Approved
LabetalolThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Labetalol.Approved
LacidipineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Lacidipine.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Levobupivacaine.Approved
LevodopaAldesleukin may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Levosimendan.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Lisinopril.Approved, Investigational
LofexidineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Lofexidine.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Losartan.Approved
MannitolThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Mannitol.Approved, Investigational
ME-609ME-609 may decrease the antineoplastic activities of Aldesleukin.Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Mecamylamine.Approved
MedrysoneMedrysone may decrease the antineoplastic activities of Aldesleukin.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Aldesleukin.Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Aldesleukin.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Methyclothiazide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Methyldopa.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Aldesleukin.Approved
MethylprednisoloneMethylprednisolone may decrease the antineoplastic activities of Aldesleukin.Approved, Vet Approved
MetipranololThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Metolazone.Approved
MetoprololThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Metoprolol.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Minoxidil.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Moexipril.Approved
MometasoneMometasone may decrease the antineoplastic activities of Aldesleukin.Approved, Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Morphine.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Moxonidine.Approved
NabiloneThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nabilone.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nadolol.Approved
NCX 1022NCX 1022 may decrease the antineoplastic activities of Aldesleukin.Investigational
NebivololThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nebivolol.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nesiritide.Approved, Investigational
NicardipineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nicardipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Aldesleukin.Approved
NifedipineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nifedipine.Approved
NilvadipineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nilvadipine.Approved
NimodipineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nitroprusside.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Obinutuzumab.Approved
OleandrinAnvirzel may decrease the cardiotoxic activities of Aldesleukin.Experimental
Oleoyl-estroneOleoyl estrone may decrease the antineoplastic activities of Aldesleukin.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Olmesartan.Approved, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Aldesleukin.Approved
OxprenololThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Oxprenolol.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Aldesleukin.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Papaverine.Approved
ParamethasoneParamethasone may decrease the antineoplastic activities of Aldesleukin.Approved
Peginterferon alfa-2aThe risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Aldesleukin.Approved, Investigational
Peginterferon alfa-2bThe risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Aldesleukin.Approved
PenbutololThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Penbutolol.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Aldesleukin.Approved, Vet Approved
PerindoprilThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Perindopril.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Phenelzine.Approved
PhenobarbitalPhenobarbital may increase the hypotensive activities of Aldesleukin.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Phenoxybenzamine.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Phentolamine.Approved
PindololThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Pipamperone.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Pramipexole.Approved, Investigational
PrasteronePrasterone may decrease the antineoplastic activities of Aldesleukin.Approved, Nutraceutical
Prasterone sulfatedehydroepiandrosterone sulfate may decrease the antineoplastic activities of Aldesleukin.Investigational
PrazosinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Prazosin.Approved
PrednicarbatePrednicarbate may decrease the antineoplastic activities of Aldesleukin.Approved
PrednisolonePrednisolone may decrease the antineoplastic activities of Aldesleukin.Approved, Vet Approved
PrednisonePrednisone may decrease the antineoplastic activities of Aldesleukin.Approved, Vet Approved
PregnenolonePregnenolone may decrease the antineoplastic activities of Aldesleukin.Experimental
PrimidonePrimidone may increase the hypotensive activities of Aldesleukin.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Propranolol.Approved, Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Quinapril.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Ramipril.Approved
RasagilineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Remifentanil.Approved
ReserpineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Reserpine.Approved
RimexoloneRimexolone may decrease the antineoplastic activities of Aldesleukin.Approved
RiociguatThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Riociguat.Approved
RisperidoneAldesleukin may increase the hypotensive activities of Risperidone.Approved, Investigational
RopiniroleThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Sacubitril.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Aldesleukin.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Selegiline.Approved, Investigational, Vet Approved
SevofluraneThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Sevoflurane.Approved, Vet Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Sotalol.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Spironolactone.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Sufentanil.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Tamsulosin.Approved, Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Telmisartan.Approved, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Terazosin.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Aldesleukin.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Aldesleukin.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Thioridazine.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Timolol.Approved
TixocortolTixocortol may decrease the antineoplastic activities of Aldesleukin.Approved
TizanidineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Tizanidine.Approved
TolazolineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Tolcapone.Approved, Withdrawn
TorasemideThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Trandolapril.Approved
TranylcypromineThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Tranylcypromine.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Aldesleukin.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamcinoloneTriamcinolone may decrease the antineoplastic activities of Aldesleukin.Approved, Vet Approved
TriamtereneThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Triamterene.Approved
ValsartanThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Valsartan.Approved, Investigational
VerapamilThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Verapamil.Approved
Food InteractionsNot Available
References
Synthesis Reference

Hans-Ake Fabricius, Roland Stahn, "Serum-free and mitogen-free T-cell growth factor and process for making same." U.S. Patent US4464355, issued May, 1971.

US4464355
General ReferencesNot Available
External Links
ATC CodesL03AC01 — Aldesleukin
AHFS Codes
  • 10:00.00
PDB Entries
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentMelanoma (Skin) / Renal Cancers1
0CompletedTreatmentRenal Cancers1
0RecruitingTreatmentMelanoma (Skin) / Skin Cancers1
1Active Not RecruitingTreatmentLymphoma, B-Cell / Malignant Lymphomas1
1Active Not RecruitingTreatmentMelanoma (Skin)1
1Active Not RecruitingTreatmentOvarian Cancer Metastatic1
1Active Not RecruitingTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
1CompletedTreatmentAnaplastic Astrocytoma (AA) / Anaplastic Ependymoma / Anaplastic Meningioma / Anaplastic Oligodendroglioma (AO) / Brain Stem Gliomas / Ependymoblastoma / Giant Cell Glioblastoma / Glioblastomas / Gliosarcoma / Grade III Meningioma / Meningeal Hemangiopericytoma / Mixed Gliomas / Neoplasms, Brain / Pineal Gland Astrocytoma1
1CompletedTreatmentB-Cell Chronic Lymphocytic Leukemia / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Splenic Marginal Zone Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
1CompletedTreatmentB-cell Adult Acute Lymphoblastic Leukemia / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Splenic Marginal Zone Lymphoma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma1
1CompletedTreatmentBrain and Central Nervous System Tumors1
1CompletedTreatmentCancer, Breast1
1CompletedTreatmentCancer, Breast / Metastatic Cancers1
1CompletedTreatmentCancer, Ovarian1
1CompletedTreatmentCancers1
1CompletedTreatmentCytomegalovirus Retinitis / Human Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentDiabetes, Diabetes Mellitus Type 11
1CompletedTreatmentDisseminated Neuroblastoma / Recurrent Neuroblastoma / Regional Neuroblastoma1
1CompletedTreatmentDrug Extravasation / Renal Cancers1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections9
1CompletedTreatmentLeukemias1
1CompletedTreatmentLeukemias / Malignant Lymphomas1
1CompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm1
1CompletedTreatmentLeukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
1CompletedTreatmentLeukemias / Myelodysplastic Syndrome1
1CompletedTreatmentLeukemias / Myelodysplastic Syndromes1
1CompletedTreatmentLeukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
1CompletedTreatmentMalignant Lymphomas4
1CompletedTreatmentMalignant Lymphomas / Small Intestine Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentMelanoma1
1CompletedTreatmentMelanoma (Skin)5
1CompletedTreatmentMelanoma (Skin) / Renal Cancers1
1CompletedTreatmentMelanoma / Renal Cancers1
1CompletedTreatmentMetastatic Melanoma / Renal Cell Adenocarcinoma1
1CompletedTreatmentNeuroblastomas1
1CompletedTreatmentRecurrent Melanoma / Stage IV Melanoma2
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific2
1CompletedTreatmentWiskott-Aldrich Syndrome (WAS) / X-linked Thrombocytopenia1
1Enrolling by InvitationTreatmentEsophageal Cancers / Gallbladder Cancer / Liver Cancer / Malignant intestinal neoplasms / Malignant Neoplasm of Pancreas / Malignant Neoplasm of Stomach1
1Not Yet RecruitingTreatmentFallopian Tube Carcinoma / Ovarian Carcinoma / Primary Peritoneal Cancer / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma1
1Not Yet RecruitingTreatmentGastrointestinal Cancer Metastatic1
1Not Yet RecruitingTreatmentHigh Grade Squamous Intraepithelial Lesion / HPV-16 / Human Papillomavirus1
1Not Yet RecruitingTreatmentMelanoma and Other Malignant Neoplasms of Skin1
1RecruitingBasic ScienceSoft Tissue Sarcoma Adult1
1RecruitingTreatmentAdult Solid Neoplasm / Childhood Solid Neoplasm / Neoplasms, Metastatic1
1RecruitingTreatmentAnal Carcinoma / Cervical Cancers / Oropharyngeal Cancers / Penile Cancer / Vaginal Cancers1
1RecruitingTreatmentCancers / Tumors, Solid1
1RecruitingTreatmentChronic Graft Versus Host Disease1
1RecruitingTreatmentHigh-risk Tumor / Malignant Lymphomas / Neuroblastomas1
1RecruitingTreatmentMelanoma2
1RecruitingTreatmentMetastatic Renal Cell Carcinoma1
1RecruitingTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1RecruitingTreatmentVascularized Composite Allotransplantation1
1TerminatedTreatmentCancer, Breast / Cancer, Ovarian / Colorectal Cancers / Lung Cancers / Malignant Neoplasm of Pancreas / Malignant Neoplasm of Stomach / Unspecified Adult Solid Tumor, Protocol Specific1
1TerminatedTreatmentCancer, Breast / Malignant Lymphomas1
1TerminatedTreatmentChronic Hepatitis C Infection1
1TerminatedTreatmentHIV-1 Infections1
1TerminatedTreatmentLung Cancers1
1TerminatedTreatmentMelanoma / Metastatic Cancers1
1TerminatedTreatmentMetastatic Cancers1
1TerminatedTreatmentNeuroblastomas1
1TerminatedTreatmentRecurrent Neuroblastoma1
1TerminatedTreatmentRenal Cancers1
1TerminatedTreatmentStage IV Melanoma1
1TerminatedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1Unknown StatusTreatmentCancer, Breast1
1Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1Unknown StatusTreatmentMalignant Lymphomas1
1Unknown StatusTreatmentNeuroblastomas / Sarcomas1
1WithdrawnTreatmentMalignant Ovarian Clear Cell Tumor / Malignant Ovarian Serous Tumor / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Stage IIIA Fallopian Tube Cancer / Stage IIIA Ovarian Cancer / Stage IIIA Primary Peritoneal Cancer / Stage IIIB Fallopian Tube Cancer / Stage IIIB Ovarian Cancer / Stage IIIB Primary Peritoneal Cancer / Stage IIIC Fallopian Tube Cancer / Stage IIIC Ovarian Cancer / Stage IIIC Primary Peritoneal Cancer / Stage IV Fallopian Tube Cancer / Stage IV Ovarian Cancer / Stage IV Primary Peritoneal Cancer1
1WithdrawnTreatmentMetastatic Melanoma1
1, 2Active Not RecruitingBasic ScienceDiabetes, Diabetes Mellitus Type 11
1, 2Active Not RecruitingTreatmentClear Cell Renal Cell Carcinoma / Metastatic Renal Cell Cancer / Stage III Renal Cell Cancer / Stage IV Renal Cell Cancer1
1, 2Active Not RecruitingTreatmentEwing's Sarcoma (ES) / Lung Cancer Metastatic / Sarcoma, Osteogenic / Sarcomas / Tumors, Solid1
1, 2Active Not RecruitingTreatmentMelanoma1
1, 2Active Not RecruitingTreatmentTransplantation, Kidney1
1, 2CompletedBasic ScienceDiabetes, Diabetes Mellitus Type 11
1, 2CompletedTreatmentAcute Myelogenous Leukaemia (AML)1
1, 2CompletedTreatmentAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / B-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Childhood Chronic Myelogenous Leukemia / Childhood Myelodysplastic Syndromes / Chronic Myelomonocytic Leukemia / Essential Thrombocythemia (ET) / Polycythemia Vera (PV) / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Relapsing Chronic Myelogenous Leukemia / Secondary Acute Myeloid Leukemia / T-cell Adult Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia1
1, 2CompletedTreatmentCancer, Breast / Cancer, Ovarian1
1, 2CompletedTreatmentColorectal Cancers1
1, 2CompletedTreatmentCryoglobulinemia Vasculitis1
1, 2CompletedTreatmentDiabetes, Diabetes Mellitus Type 11
1, 2CompletedTreatmentGlomerulonephritis minimal lesion1
1, 2CompletedTreatmentGraft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm1
1, 2CompletedTreatmentIntraocular Melanoma / Melanoma (Skin)1
1, 2CompletedTreatmentLeukemias2
1, 2CompletedTreatmentLeukemias / Malignant Lymphomas1
1, 2CompletedTreatmentMalignant Lymphomas1
1, 2CompletedTreatmentMalignant Neoplasm of Prostate1
1, 2CompletedTreatmentMelanoma1
1, 2CompletedTreatmentMelanoma (Skin)4
1, 2CompletedTreatmentMetastatic Cancers / Metastatic Melanoma / Renal Cancers1
1, 2CompletedTreatmentMetastatic Cancers / Renal Cancers1
1, 2CompletedTreatmentMetastatic Melanoma / Metastatic Renal Cell Carcinoma1
1, 2CompletedTreatmentNeuroblastomas1
1, 2CompletedTreatmentRecurrent Melanoma / Stage IV Melanoma2
1, 2CompletedTreatmentRenal Cancers1
1, 2No Longer AvailableNot AvailableMelanoma (Skin)1
1, 2Not Yet RecruitingTreatmentAcute Myeloid Leukaemias (AML) / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia1
1, 2Not Yet RecruitingTreatmentInflammation, Brain1
1, 2Not Yet RecruitingTreatmentLeukemia, Myelomonocytic, Chronic1
1, 2RecruitingTreatmentAdvanced Pleural Malignant Mesothelioma / HLA-A*0201 Positive Cells Present / Recurrent Non-Small Cell Lung Carcinoma / Recurrent Pleural Malignant Mesothelioma / Stage III Non-Small Cell Lung Cancer / Stage III Pleural Mesothelioma / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer / Stage IV Pleural Mesothelioma1
1, 2RecruitingTreatmentBrain Cancer / Glioblastomas / Malignant Gliomas1
1, 2RecruitingTreatmentCancer, Breast / Cancer, Ovarian / CD70 Expressing Cancers / Malignant Neoplasm of Pancreas / Melanoma / Renal Cell Adenocarcinoma1
1, 2RecruitingTreatmentCancer, Breast / Cervical Cancers / Malignant Melanoma / Metastatic Cancer That Express the MAGE-A3-DP4 Antigen / Oesophageal Carcinoma / Sarcomas / Urothelial Cancer1
1, 2RecruitingTreatmentCancer, Breast / Cervical Cancers / Malignant Melanoma / Metastatic Cancer That Express the MAGE-A3-HLA A01 Antigen / Metastatic Cancers / Metastatic Melanoma That Express the MAGE-A3-HLA A01 Antigen / Oesophageal Carcinoma / Sarcomas / Urothelial Cancer1
1, 2RecruitingTreatmentCancer, Ovarian / Cervical Cancers / Lung Cancers / Malignant Neoplasm of Pancreas / Mesothelioma / Metastatic Cancers / Ovarian1
1, 2RecruitingTreatmentDesmoplastic Small Round Cell Tumor (DSRCT) / Disseminated Neuroblastoma / Metastatic Osteosarcoma / Recurrent Neuroblastoma / Recurrent Osteosarcoma1
1, 2RecruitingTreatmentGastrointestinal Cancers / Malignant Neoplasm of Colon / Malignant Neoplasm of Pancreas / Malignant Neoplasm of Stomach / Rectal Carcinoma1
1, 2RecruitingTreatmentIschaemic Heart Diseases1
1, 2RecruitingTreatmentLeukemia, Myeloid, Acute1
1, 2RecruitingTreatmentLeukemias1
1, 2RecruitingTreatmentMelanoma1
1, 2RecruitingTreatmentMetastatic Melanoma1
1, 2RecruitingTreatmentMetastatic Renal Cell Carcinoma1
1, 2RecruitingTreatmentPleural Mesotheliomas1
1, 2SuspendedTreatmentAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Adult Myelodysplastic Syndrome / Childhood Myelodysplastic Syndrome / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Secondary Acute Myeloid Leukemia / Therapy-Related Acute Myeloid Leukemia1
1, 2SuspendedTreatmentPancreatic Adenocarcinoma Metastatic / Recurrent Pancreatic Carcinoma / Stage III Pancreatic Cancer / Stage IV Pancreatic Cancer1
1, 2TerminatedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Blastic Phase Chronic Myelogenous Leukemia / Childhood Chronic Myelogenous Leukemia / Childhood Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Relapsing Chronic Myelogenous Leukemia / Secondary Acute Myeloid Leukemia1
1, 2TerminatedTreatmentLeukemias / Malignant Lymphomas1
1, 2TerminatedTreatmentMalignant Melanoma / Melanoma / Melanoma, Experimental1
1, 2TerminatedTreatmentMetastatic Cancers1
1, 2TerminatedTreatmentMetastatic Cancers / Metastatic Melanoma / Metastatic Renal Cancer1
1, 2TerminatedTreatmentRecurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Stage I Cutaneous T-cell Non-Hodgkin Lymphoma / Stage I Mycosis Fungoides/Sezary Syndrome / Stage II Cutaneous T-cell Non-Hodgkin Lymphoma / Stage II Mycosis Fungoides/Sezary Syndrome / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Mycosis Fungoides/Sezary Syndrome / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Mycosis Fungoides/Sezary Syndrome1
1, 2TerminatedTreatmentRecurrent Melanoma / Stage III Melanoma / Stage IV Melanoma1
1, 2TerminatedTreatmentRecurrent Merkel Cell Carcinoma / Stage IV Merkel Cell Carcinoma1
1, 2Unknown StatusTreatmentCancer, Breast1
1, 2Unknown StatusTreatmentMelanoma (Skin)1
1, 2Unknown StatusTreatmentNeuroblastomas1
1, 2WithdrawnTreatmentCancer, Breast1
1, 2WithdrawnTreatmentMelanoma1
1, 2WithdrawnTreatmentMetastatic Thyroid Cancer1
2Active Not RecruitingPreventionGraft Versus Host Disease (GVHD)1
2Active Not RecruitingTreatmentHigh Risk Non-Hodgkin's Lymphoma1
2Active Not RecruitingTreatmentLeukemias1
2Active Not RecruitingTreatmentMalignant Lymphomas1
2Active Not RecruitingTreatmentMelanoma3
2Active Not RecruitingTreatmentMetastatic Melanoma2
2Active Not RecruitingTreatmentMetastatic Melanoma / Skin Cancers1
2Active Not RecruitingTreatmentMetastatic Ocular Melanoma / Metastatic Uveal Melanoma1
2Active Not RecruitingTreatmentMetastatic Renal Cell Carcinoma1
2Active Not RecruitingTreatmentRecurrent Melanoma / Stage IIIA Melanoma / Stage IIIB Melanoma / Stage IIIC Melanoma / Stage IV Melanoma1
2Active Not RecruitingTreatmentRecurrent Melanoma / Stage IIIA Skin Melanoma / Stage IIIB Skin Melanoma / Stage IIIC Skin Melanoma / Stage IV Skin Melanoma1
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / All / AML / Chronic Myelogenous Leukemia (CML) / Lymphoma, Hodgkins / Myelodysplastic Syndrome / Myeloproliferative Disorders / Non-Hodgkin's Lymphoma (NHL) / Non-malignant Diseases Requiring Allogeneic HSCT1
2CompletedTreatmentAdult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Childhood Acute Myeloid Leukemia in Remission / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia1
2CompletedTreatmentAmyotrophic Lateral Sclerosis (ALS)1
2CompletedTreatmentAnal Carcinoma / Cervical Cancers / Oropharyngeal Cancers / Penile Cancer / Vaginal Cancers2
2CompletedTreatmentAnti-p53 TCR-Gene1
2CompletedTreatmentBrain and Central Nervous System Tumors3
2CompletedTreatmentCancer, Breast / Cancer, Ovarian / Cervical Cancers / Colorectal Cancers / Lung Cancers / Malignant Neoplasm of Pancreas1
2CompletedTreatmentCancer, Breast / Cancer, Ovarian / Chronic Myeloproliferative Disorders / Gestational Trophoblastic Disease / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Neuroblastomas / Renal Cancers / Sarcomas / Testicular germ cell tumour1
2CompletedTreatmentCancer, Breast / Esophageal Cancers / Lung Cancers / Malignant Neoplasm of Pancreas / Malignant Neoplasm of Stomach / Unspecified Adult Solid Tumor, Protocol Specific1
2CompletedTreatmentChronic Myelogenous Leukemia (CML) / Leukemias1
2CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Precancerous/Nonmalignant Condition / Unspecified Adult Solid Tumor, Protocol Specific1
2CompletedTreatmentColorectal Cancers / Endometrial Cancers / Head and Neck Carcinoma / Liver Cancer / Lung Cancers / Malignant Neoplasm of Pancreas / Melanoma (Skin) / Testicular germ cell tumour / Unspecified Adult Solid Tumor, Protocol Specific1
2CompletedTreatmentEstrogen Receptor-negative Breast Cancer / Estrogen Receptor-Positive Breast Cancer / Inflammatory carcinoma of the breast / Male Breast Cancer / Progesterone Receptor-negative Breast Cancer / Progesterone Receptor-positive Breast Cancer / Stage IIIB Breast Cancer / Stage IV Breast Cancer1
2CompletedTreatmentHER2-positive Breast Cancer / Male Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections10
2CompletedTreatmentLeukemias4
2CompletedTreatmentLiver Cancer1
2CompletedTreatmentMalignant Lymphomas3
2CompletedTreatmentMalignant Lymphomas / Unspecified Adult Solid Tumor, Protocol Specific / Unspecified Childhood Solid Tumor, Protocol Specific1
2CompletedTreatmentMalignant Melanoma1
2CompletedTreatmentMalignant Melanoma / Melanoma / Melanoma, Experimental1
2CompletedTreatmentMalignant Neoplasm of Prostate1
2CompletedTreatmentMelanoma1
2CompletedTreatmentMelanoma (Skin)20
2CompletedTreatmentMelanoma (Skin) / Renal Cancers1
2CompletedTreatmentMelanoma (Skin) / Renal Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
2CompletedTreatmentMelanoma (Skin) / Unspecified Adult Solid Tumor, Protocol Specific1
2CompletedTreatmentMelanoma / Metastatic Melanoma / Skin Cancers1
2CompletedTreatmentMelanoma / Skin Cancers2
2CompletedTreatmentMetastatic Kidney Cancer / Metastatic Melanoma1
2CompletedTreatmentMetastatic Melanoma1
2CompletedTreatmentMetastatic Melanoma / Skin Cancers2
2CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
2CompletedTreatmentRecurrent Melanoma / Stage IV Melanoma1
2CompletedTreatmentRecurrent Renal Cell Cancer / Stage III Renal Cell Cancer / Stage IV Renal Cell Cancer1
2CompletedTreatmentRefractory Multiple Myeloma / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2CompletedTreatmentRenal Cancers4
2CompletedTreatmentRenal Cell Carcinoma Recurrent / Stage IV Renal Cell Cancer1
2RecruitingBasic ScienceTransplantation, Liver1
2RecruitingTreatmentAcute Myeloid Leukaemias (AML) / Leukemias / Myeloid Leukemias1
2RecruitingTreatmentAdenocarcinomas / Advanced NSCLC / Carcinoma, Adenosquamous / Metastatic Non-Small Cell Lung Cancer / Squamous Cell Carcinoma (SCC)1
2RecruitingTreatmentCancer, Breast / Hepatocellular Cancer / Melanoma / Metastatic Cancers Other Than Melanoma That Express ESO Antigen / Non-Small-Cell Lung Carcinoma (NSCLC) / Synovial Sarcoma1
2RecruitingTreatmentChronic Graft Versus Host Disease2
2RecruitingTreatmentMelanoma2
2RecruitingTreatmentMetastatic Cholangiocarcinoma / Metastatic Colorectal Cancers / Metastatic Gastric Cancers / Metastatic Hepatocellular Carcinoma / Pancreatic Cancer Metastatic1
2RecruitingTreatmentMetastatic Melanoma2
2RecruitingTreatmentMetastatic Melanoma / Stage III Mucosal Melanoma of the Head and Neck / Stage IIIA Skin Melanoma / Stage IIIB Skin Melanoma / Stage IIIC Skin Melanoma / Stage IV Skin Melanoma / Stage IVA Mucosal Melanoma of the Head and Neck / Stage IVB Mucosal Melanoma of the Head and Neck / Stage IVC Mucosal Melanoma of the Head and Neck1
2RecruitingTreatmentNeoplasms, Malignant1
2RecruitingTreatmentNeuroblastomas1
2RecruitingTreatmentRecurrent B-Cell Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood B-Lymphoblastic Lymphoma1
2RecruitingTreatmentRenal Cancers1
2RecruitingTreatmentRenal Cell Adenocarcinoma1
2RecruitingTreatmentStage IIIA Skin Melanoma / Stage IIIB Skin Melanoma / Stage IIIC Skin Melanoma / Stage IV Skin Melanoma / Stages III Skin Melanoma1
2SuspendedTreatmentBrain and Central Nervous System Tumors1
2TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myeloid Leukaemias (AML) / Chronic Myelogenous Leukemia (CML) / Granulocytic Sarcoma / Juvenile Myelomonocytic Leukemia (JMML) / Myelodysplastic Syndromes (MDS) / Non-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentCancer, Breast1
2TerminatedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cavity Cancer1
2TerminatedTreatmentLeukemias1
2TerminatedTreatmentLeukemias / Myelodysplastic Syndromes1
2TerminatedTreatmentLeukemias / Pediatric Cancer1
2TerminatedTreatmentMalignant Lymphomas1
2TerminatedTreatmentMelanoma2
2TerminatedTreatmentMelanoma (Skin)2
2TerminatedTreatmentMelanoma (Skin) / Renal Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
2TerminatedTreatmentMelanoma / Skin Cancers2
2TerminatedTreatmentMetastatic Cancers / Metastatic Melanoma1
2TerminatedTreatmentMetastatic Cancers / Metastatic Melanoma / Metastatic Renal Cell Cancer1
2TerminatedTreatmentMetastatic Cutaneous Melanoma1
2TerminatedTreatmentMetastatic Melanoma / Metastatic Renal Cancer1
2TerminatedTreatmentMetastatic Melanoma / Skin Cancers3
2TerminatedTreatmentNeoplasms, Ovarian1
2TerminatedTreatmentNeuroblastomas2
2TerminatedTreatmentNon-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentRecurrent Melanoma / Stage IV Melanoma1
2TerminatedTreatmentRenal Cell Adenocarcinoma1
2TerminatedTreatmentStage IV Melanoma1
2Unknown StatusTreatmentLung Cancers1
2Unknown StatusTreatmentMelanoma (Skin)1
2Unknown StatusTreatmentMetastatic Renal Cell Carcinoma1
2Unknown StatusTreatmentNeuroblastomas1
2Unknown StatusTreatmentRenal Cancers9
2WithdrawnTreatmentAcute Myelogenous Leukaemia (AML)1
2WithdrawnTreatmentCrohn's Disease (CD)1
2WithdrawnTreatmentMelanoma (Skin)1
2, 3CompletedTreatmentMalignant Lymphomas1
3CompletedTreatmentAdult Acute Basophilic Leukemia / Adult Acute Eosinophilic Leukemia / Adult Acute Erythroid Leukemia (M6) / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Childhood Acute Basophilic Leukemia / Childhood Acute Eosinophilic Leukemia / Childhood Acute Erythroleukemia (M6) / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Minimally Differentiated Myeloid Leukemia (M0) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5) / Childhood Acute Monocytic Leukemia (M5b) / Childhood Acute Myeloblastic Leukemia With Maturation (M2) / Childhood Acute Myeloblastic Leukemia Without Maturation (M1) / Childhood Acute Myelomonocytic Leukemia (M4) / Childhood Myelodysplastic Syndromes / De Novo Myelodysplastic Syndromes / Untreated Adult Acute Myeloid Leukemia / Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies1
3CompletedTreatmentCancer, Breast1
3CompletedTreatmentChildhood Acute Erythroleukemia (M6) / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Monocytic Leukemia (M5b) / Childhood Acute Myeloblastic Leukemia With Maturation (M2) / Childhood Acute Myeloblastic Leukemia Without Maturation (M1) / Childhood Acute Myelomonocytic Leukemia (M4) / Childhood Myelodysplastic Syndromes / Chronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndromes / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Refractory Anemia With Ringed Sideroblasts / Secondary Myelodysplastic Syndromes / Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies1
3CompletedTreatmentDisseminated Neuroblastoma / Localized Resectable Neuroblastoma / Localized Unresectable Neuroblastoma / Regional Neuroblastoma / Stage 4 Neuroblastoma / Stage 4S Neuroblastoma1
3CompletedTreatmentGraft Versus Host Disease (GVHD) / Malignant Lymphomas1
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections4
3CompletedTreatmentLeukemias2
3CompletedTreatmentLocalized Resectable Neuroblastoma / Localized Unresectable Neuroblastoma / Recurrent Neuroblastoma / Regional Neuroblastoma / Stage 4 Neuroblastoma / Stage 4S Neuroblastoma1
3CompletedTreatmentMelanoma (Skin)2
3CompletedTreatmentMelanoma / Skin Cancers1
3CompletedTreatmentRecurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma1
3CompletedTreatmentRecurrent Melanoma / Stage IIIA Skin Melanoma / Stage IIIB Skin Melanoma / Stage IIIC Skin Melanoma / Stage IV Skin Melanoma1
3CompletedTreatmentRenal Cancers6
3Not Yet RecruitingTreatmentChildhood Ganglioneuroblastoma / Childhood Neuroblastoma / NMYC Gene Amplification / Recurrent Neuroblastoma1
3RecruitingTreatmentMetastatic Melanoma1
3RecruitingTreatmentNeuroblastomas1
3Unknown StatusTreatmentHead and Neck Carcinoma1
3Unknown StatusTreatmentLeukemias2
3Unknown StatusTreatmentMelanoma (Skin) / Metastatic Cancers1
4CompletedTreatmentAcute Myeloid Leukaemias (AML)1
4CompletedTreatmentRenal Cancers1
4Not Yet RecruitingTreatmentLiver Diseases / Transplantations1
4TerminatedTreatmentMetastatic Melanoma1
Not AvailableActive Not RecruitingNot AvailableMalignant Melanoma1
Not AvailableActive Not RecruitingTreatmentMetastatic Melanoma2
Not AvailableCompletedNot AvailableHead and Neck Carcinoma1
Not AvailableCompletedTreatmentChronic Hepatitis C Infection / Human Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections5
Not AvailableNot Yet RecruitingTreatmentHLA-A2 Positive Cells Present / Metastatic Malignant Neoplasm / Metastatic Malignant Neoplasm in the Brain1
Not AvailableRecruitingTreatmentAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia1
Not AvailableTerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableUnknown StatusTreatmentMelanoma (Skin) / Renal Cancers1
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
InjectionIntravenous1.1 mg/mL
Injection, powder, lyophilized, for solutionIntravenous1.1 mg/mL
Powder, for solutionIntravenous22000000 unit
Prices
Unit descriptionCostUnit
Proleukin 22 million unit vial1092.34USD each
Proleukin 22000000 unit Solution Vial976.66USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateLiquid
Experimental Properties
PropertyValueSource
hydrophobicity-0.192Not Available
isoelectric point7.31Not Available
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonistmodulator
General Function:
Interleukin-2 receptor activity
Specific Function:
Receptor for interleukin-2. This beta subunit is involved in receptor mediated endocytosis and transduces the mitogenic signals of IL2.
Gene Name:
IL2RB
Uniprot ID:
P14784
Uniprot Name:
Interleukin-2 receptor subunit beta
Molecular Weight:
61116.59 Da
References
  1. Stauber DJ, Debler EW, Horton PA, Smith KA, Wilson IA: Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor. Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2788-93. Epub 2006 Feb 13. [PubMed:16477002 ]
  2. Steppan S, Eckart MR, Bajsarowicz K, Sternberg LR, Greve JM, Cassell DJ: Reduced secondary cytokine induction by BAY 50-4798, a high-affinity receptor-specific interleukin-2 analog. J Interferon Cytokine Res. 2006 Mar;26(3):171-8. [PubMed:16542139 ]
  3. Cornish GH, Sinclair LV, Cantrell DA: Differential regulation of T-cell growth by IL-2 and IL-15. Blood. 2006 Jul 15;108(2):600-8. Epub 2006 Mar 28. [PubMed:16569767 ]
  4. Lee KD, Chen HW, Chen CC, Shih YC, Liu HK, Cheng ML: Construction and characterization of a novel fusion protein consisting of anti-CD3 antibody fused to recombinant interleukin-2. Oncol Rep. 2006 May;15(5):1211-6. [PubMed:16596189 ]
  5. Maclennan C, Hutchinson P, Holdsworth S, Bardin PG, Freezer NJ: Airway inflammation in asymptomatic children with episodic wheeze. Pediatr Pulmonol. 2006 Jun;41(6):577-83. [PubMed:16617454 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonistmodulator
General Function:
Interleukin-2 receptor activity
Specific Function:
Receptor for interleukin-2. The receptor is involved in the regulation of immune tolerance by controlling regulatory T cells (TREGs) activity. TREGs suppress the activation and expansion of autoreactive T cells.
Gene Name:
IL2RA
Uniprot ID:
P01589
Uniprot Name:
Interleukin-2 receptor subunit alpha
Molecular Weight:
30818.915 Da
References
  1. Waldmann TA: Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J Clin Immunol. 2007 Jan;27(1):1-18. Epub 2007 Jan 11. [PubMed:17216565 ]
  2. Recchia F, Cesta A, Rea S: Low dose interleukin-2 and 13-cis-retinoic acid as maintenance therapy in patients with solid tumors responsive to chemotherapy. J Exp Clin Cancer Res. 2003 Dec;22(4 Suppl):135-43. [PubMed:16767920 ]
  3. Waldmann TA: Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma. Oncogene. 2007 May 28;26(25):3699-703. [PubMed:17530023 ]
  4. Vlad G, Ho EK, Vasilescu ER, Fan J, Liu Z, Cai JW, Jin Z, Burke E, Deng M, Cadeiras M, Cortesini R, Itescu S, Marboe C, Mancini D, Suciu-Foca N: Anti-CD25 treatment and FOXP3-positive regulatory T cells in heart transplantation. Transpl Immunol. 2007 Jul;18(1):13-21. Epub 2007 Apr 2. [PubMed:17584597 ]
  5. Liu BY, Zhu P, Luo HB, Fu N: [Screening of short peptides binding to cell surface interleukin-2 receptor alpha chain]. Nan Fang Yi Ke Da Xue Xue Bao. 2006 Jul;26(7):971-4. [PubMed:16864089 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  7. Ouyang Y, Kaminski NE: Phospholipase A2 inhibitors p-bromophenacyl bromide and arachidonyl trifluoromethyl ketone suppressed interleukin-2 (IL-2) expression in murine primary splenocytes. Arch Toxicol. 1999 Feb;73(1):1-6. [PubMed:10207608 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Interleukin-2 binding
Specific Function:
Common subunit for the receptors for a variety of interleukins.
Gene Name:
IL2RG
Uniprot ID:
P31785
Uniprot Name:
Cytokine receptor common subunit gamma
Molecular Weight:
42286.68 Da
References
  1. Stauber DJ, Debler EW, Horton PA, Smith KA, Wilson IA: Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor. Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2788-93. Epub 2006 Feb 13. [PubMed:16477002 ]
  2. Shibata F, Toma T, Wada T, Inoue M, Tone Y, Ohta K, Kasahara Y, Sano F, Kimura M, Ikeno M, Koizumi S, Yachie A: Skin infiltration of CD56(bright) CD16(-) natural killer cells in a case of X-SCID with Omenn syndrome-like manifestations. Eur J Haematol. 2007 Jul;79(1):81-5. [PubMed:17598841 ]
  3. Fonseca SG, Reis MM, Coelho V, Nogueira LG, Monteiro SM, Mairena EC, Bacal F, Bocchi E, Guilherme L, Zheng XX, Liew FY, Higuchi ML, Kalil J, Cunha-Neto E: Locally produced survival cytokines IL-15 and IL-7 may be associated to the predominance of CD8+ T cells at heart lesions of human chronic Chagas disease cardiomyopathy. Scand J Immunol. 2007 Aug-Sep;66(2-3):362-71. [PubMed:17635814 ]
  4. Blank RB, Lamb EW, Tocheva AS, Crow ET, Lim KC, McKerrow JH, Davies SJ: The common gamma chain cytokines interleukin (IL)-2 and IL-7 indirectly modulate blood fluke development via effects on CD4+ T cells. J Infect Dis. 2006 Dec 1;194(11):1609-16. Epub 2006 Oct 23. [PubMed:17083048 ]
  5. Smyth CM, Ginn SL, Deakin CT, Logan GJ, Alexander IE: Limiting {gamma}c expression differentially affects signaling via the interleukin (IL)-7 and IL-15 receptors. Blood. 2007 Jul 1;110(1):91-8. Epub 2007 Mar 15. [PubMed:17363735 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Uniprot Name:
Prostaglandin G/H synthase 2
Molecular Weight:
68995.625 Da
References
  1. Pyeon D, Diaz FJ, Splitter GA: Prostaglandin E(2) increases bovine leukemia virus tax and pol mRNA levels via cyclooxygenase 2: regulation by interleukin-2, interleukin-10, and bovine leukemia virus. J Virol. 2000 Jun;74(12):5740-5. [PubMed:10823885 ]
  2. Hamada T, Tsuchihashi S, Avanesyan A, Duarte S, Moore C, Busuttil RW, Coito AJ: Cyclooxygenase-2 deficiency enhances Th2 immune responses and impairs neutrophil recruitment in hepatic ischemia/reperfusion injury. J Immunol. 2008 Feb 1;180(3):1843-53. [PubMed:18209082 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Phospholipase a2 activity
Specific Function:
Selectively hydrolyzes arachidonyl phospholipids in the sn-2 position releasing arachidonic acid. Together with its lysophospholipid activity, it is implicated in the initiation of the inflammatory response.
Gene Name:
PLA2G4A
Uniprot ID:
P47712
Uniprot Name:
Cytosolic phospholipase A2
Molecular Weight:
85238.2 Da
References
  1. Wolbink GJ, Schalkwijk C, Baars JW, Wagstaff J, van den Bosch H, Hack CE: Therapy with interleukin-2 induces the systemic release of phospholipase-A2. Cancer Immunol Immunother. 1995 Nov;41(5):287-92. [PubMed:8536274 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Uniprot Name:
Cytochrome P450 3A4
Molecular Weight:
57342.67 Da
References
  1. Elkahwaji J, Robin MA, Berson A, Tinel M, Letteron P, Labbe G, Beaune P, Elias D, Rougier P, Escudier B, Duvillard P, Pessayre D: Decrease in hepatic cytochrome P450 after interleukin-2 immunotherapy. Biochem Pharmacol. 1999 Apr 15;57(8):951-4. [PubMed:10086330 ]
  2. Sunman JA, Hawke RL, LeCluyse EL, Kashuba AD: Kupffer cell-mediated IL-2 suppression of CYP3A activity in human hepatocytes. Drug Metab Dispos. 2004 Mar;32(3):359-63. [PubMed:14977871 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Xanthine oxidase activity
Specific Function:
Key enzyme in purine degradation. Catalyzes the oxidation of hypoxanthine to xanthine. Catalyzes the oxidation of xanthine to uric acid. Contributes to the generation of reactive oxygen species. Has also low oxidase activity towards aldehydes (in vitro).
Gene Name:
XDH
Uniprot ID:
P47989
Uniprot Name:
Xanthine dehydrogenase/oxidase
Molecular Weight:
146422.99 Da
References
  1. Faggioni R, Allavena P, Cantoni L, Carelli M, Demitri MT, Delgado R, Gatti S, Gnocchi P, Isetta AM, Paganin C, et al.: Mechanisms of interleukin-2-induced hydrothoraxy in mice: protective effect of endotoxin tolerance and dexamethasone and possible role of reactive oxygen intermediates. J Immunother Emphasis Tumor Immunol. 1994 Apr;15(3):194-201. [PubMed:8032542 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Uniprot Name:
Cytochrome P450 2E1
Molecular Weight:
56848.42 Da
References
  1. Elkahwaji J, Robin MA, Berson A, Tinel M, Letteron P, Labbe G, Beaune P, Elias D, Rougier P, Escudier B, Duvillard P, Pessayre D: Decrease in hepatic cytochrome P450 after interleukin-2 immunotherapy. Biochem Pharmacol. 1999 Apr 15;57(8):951-4. [PubMed:10086330 ]
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23